What is Leerink Partnrs’ Forecast for RCUS Q1 Earnings?

Arcus Biosciences, Inc. (NYSE:RCUS) – Research analysts at Leerink Partnrs issued their Q1 2026 earnings estimates for shares of Arcus Biosciences in a research report issued on Wednesday, February 26th. Leerink Partnrs analyst D. Graybosch anticipates that the company will post earnings of ($0.55) per share for the quarter. The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.15) per share. Leerink Partnrs also issued estimates for Arcus Biosciences’ Q2 2026 earnings at ($1.05) EPS, Q3 2026 earnings at ($1.06) EPS, Q4 2026 earnings at ($0.11) EPS and FY2029 earnings at $0.79 EPS.

Other equities research analysts have also recently issued research reports about the company. HC Wainwright raised Arcus Biosciences from a “neutral” rating to a “buy” rating and raised their target price for the stock from $18.00 to $24.00 in a research note on Wednesday. Wedbush reaffirmed an “outperform” rating and set a $36.00 price objective on shares of Arcus Biosciences in a research report on Thursday, November 7th. Bank of America lowered their price objective on shares of Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating for the company in a research note on Wednesday, February 19th. Finally, Morgan Stanley cut their target price on shares of Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 18th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $30.25.

Arcus Biosciences Stock Performance

RCUS stock opened at $9.87 on Thursday. The firm has a market cap of $1.04 billion, a PE ratio of -3.13 and a beta of 0.84. The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 0.08. The stock has a 50-day moving average price of $13.46 and a 200-day moving average price of $15.42. Arcus Biosciences has a 1-year low of $9.85 and a 1-year high of $20.10.

Arcus Biosciences (NYSE:RCUS) last announced its earnings results on Tuesday, February 25th. The company reported ($1.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.17) by $0.14. The business had revenue of $36.00 million during the quarter, compared to the consensus estimate of $29.38 million. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%.

Institutional Investors Weigh In On Arcus Biosciences

Several institutional investors have recently bought and sold shares of the stock. Woodline Partners LP lifted its stake in Arcus Biosciences by 1.3% during the 4th quarter. Woodline Partners LP now owns 3,523,937 shares of the company’s stock valued at $52,471,000 after acquiring an additional 45,497 shares in the last quarter. Two Sigma Advisers LP raised its holdings in shares of Arcus Biosciences by 35.8% in the fourth quarter. Two Sigma Advisers LP now owns 58,800 shares of the company’s stock valued at $876,000 after purchasing an additional 15,500 shares during the last quarter. Two Sigma Investments LP lifted its position in shares of Arcus Biosciences by 8.1% during the fourth quarter. Two Sigma Investments LP now owns 146,686 shares of the company’s stock valued at $2,184,000 after purchasing an additional 11,027 shares in the last quarter. Tema Etfs LLC purchased a new position in Arcus Biosciences during the fourth quarter worth about $331,000. Finally, ProShare Advisors LLC boosted its holdings in Arcus Biosciences by 44.4% during the fourth quarter. ProShare Advisors LLC now owns 16,379 shares of the company’s stock worth $244,000 after purchasing an additional 5,038 shares during the last quarter. Institutional investors own 92.89% of the company’s stock.

Insider Activity at Arcus Biosciences

In other Arcus Biosciences news, CFO Robert C. Goeltz II sold 3,594 shares of the business’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $15.00, for a total transaction of $53,910.00. Following the completion of the sale, the chief financial officer now directly owns 60,138 shares of the company’s stock, valued at approximately $902,070. The trade was a 5.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Yasunori Kaneko acquired 20,000 shares of the stock in a transaction dated Thursday, February 27th. The stock was bought at an average cost of $10.06 per share, with a total value of $201,200.00. Following the completion of the purchase, the director now owns 28,400 shares of the company’s stock, valued at approximately $285,704. The trade was a 238.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 12.30% of the stock is currently owned by insiders.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.